BIVI - BioVie: Four Potential Catalysts Around The Corner

• With four readouts in Parkinson’s disease, refractory ascites and Alzheimer’s disease, the coming year may be defining for BioVie.
• Topline results of the Phase 2a trial in Parkinson’s disease should in principle be released in the coming months.
• The potential risk-reward ratio is mind-blowing, but insofar as it comes to its biggest potential in neurodegenerative diseases, the stock remains highly speculative at this stage.
• The scientific background makes sense, but I am waiting for a first readout of the drug candidate for neurodegenerative diseases.

For further details see: